Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.

Oncotarget - 25 Jul 2017

Cao Yanna, Jin Yan, Yu Jinpu, Wang Jingfu, Qiu Yanli, Duan Xiaofeng, Ye Yingnan, Cheng Yanan, Dong Li, Feng Xiaolong, Wang Daowei, Li Zhongyuan, Tian Xiangdong, Wang Huijuan, Yan Jie, Zhao Qiang

Abstract excerpt

Neuroblastomas (NBs) exhibit heterogeneity and show clinically significant prognosis classified by genetic alterations. Among prognostic genes or genome factors, MYCN amplification (MNA) is the most established genomic marker of poor prognosis in patients with NB. However, the prognostic classification of more than 60% of patients without MNA has yet to be clarified. In this study, the application of target...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to DNA Copy Number Variations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genomics

Share to High-Throughput Nucleotide Sequencing

Share to N-Myc Proto-Oncogene Protein

Share to Neoplasm Staging

Share to Neuroblastoma

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 28591696
DOI: 10.18632/oncotarget.17917
PMCID: PMC5564799

Genes

EFS
MYCN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical evaluation of integrated panel testing by next-generation sequencing for somatic mutations in neuroblastomas with MYCN unamplification.PMID 28591696Read ↗

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastomaSemantic proximity Read ↗

Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.Semantic proximity Read ↗

Higher tumor mutational burden is associated with inferior outcomes among pediatric patients with neuroblastoma.Semantic proximity Read ↗

Concurrent detection of targeted copy number variants and mutations using a myeloid malignancy next generation sequencing panel allows comprehensive genetic analysis using a single testing strategySemantic proximity Read ↗

A highly malignant case of neuroblastoma with substantial increase of single-nucleotide variants and normal mismatch repair system: A case report.Semantic proximity Read ↗

Neuroblastoma Risk Assessment and Treatment Stratification with Hybrid Capture-Based Panel SequencingSemantic proximity Read ↗

Development and validation of an ultra-high sensitive next-generation sequencing assay for molecular diagnosis of clinical oncology.Semantic proximity Read ↗

Comprehensive Molecular Genetic Analysis in Glioma Patients by Next Generation SequencingSemantic proximity Read ↗

Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression.Semantic proximity Read ↗

Association of MYCN copy number with clinical features, tumor biology, and outcomes in neuroblastoma: A report from the Children's Oncology GroupSemantic proximity Read ↗

A Targeted Gene Panel for Circulating Tumor DNA Sequencing in NeuroblastomaSemantic proximity Read ↗

Addition of chromosomal microarray and next generation sequencing to FISH and classical cytogenetics enhances genomic profiling of myeloid malignancies.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.